首页> 外文期刊>Food and Nutrition Sciences >5-Aminolevulinic Acid (5-ALA): Analysis of Preclinical and Safety Literature
【24h】

5-Aminolevulinic Acid (5-ALA): Analysis of Preclinical and Safety Literature

机译:5-氨基乙酰丙酸(5-ALA):临床前和安全性文献分析

获取原文
           

摘要

Problem: 5-ALA has been used for many years at relatively high dose amounts in single doses for photodynamic therapy and immunofluorescence of tumors. An analysis of compiled data relating to safety and any side-effects about the use of 5-ALA at low doses has not yet been published. Purpose: This report analyzes data about the safety of the use of 5-Aminolevulinic Acid (5-ALA) in low doses as a supplement over an extended period of time. Methods: This investigation is a systematic analysis of the current literature ((Medline, and SBI) and snowballing techniques) related to the safety and efficacy of 5-ALA in animals and humans. Clinical trials in progress using 5-ALA were also analyzed. Constant comparative analyses were used to synthesize the findings. Results: The safety of low-dose 5-ALA as a supplement has been demonstrated by animal and human studies. The results suggest that none of the investigations document the presence of symptoms or abnormal laboratory results of clinical significance. The minor laboratory changes documented were judged not clinically significant.
机译:问题:5-ALA已以相对高的剂量单剂量用于肿瘤的光动力疗法和免疫荧光法。关于安全性和低剂量使用5-ALA的任何副作用的汇编数据的分析尚未发表。目的:本报告分析了在延长的时间内使用低剂量的5-氨基乙酰丙酸(5-ALA)作为补充剂的安全性数据。方法:本研究是对有关5-ALA在动物和人类中的安全性和有效性的现有文献((Medline和SBI)和滚雪球技术)的系统分析。还分析了使用5-ALA进行的临床试验。持续的比较分析用于综合发现。结果:低剂量的5-ALA作为补充剂的安全性已通过动物和人体研究证明。结果表明,没有任何调查记录出症状的存在或具有临床意义的异常实验室结果。记录的较小实验室变化被判断为无临床意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号